Tirzepatide vs Semaglutide for Weight Loss: What Actually Changes

What the trials measured

The evidence starts with two pivotal trials. STEP-1, published in the New England Journal of Medicine in 2021, tested semaglutide 2.4 mg once weekly in adults with obesity. SURMOUNT-1, published in the same journal in 2022, tested tirzepatide at 5, 10, and 15 mg once weekly in a similar population. Neither trial was designed as a direct head-to-head comparison, which is why a later study matters so much. SURMOUNT-5, published in NEJM in 2025, compared tirzepatide directly against semaglutide, making it the most relevant source for the question you're asking.

When you read weight loss percentages, pay attention to the estimand, which is the way researchers define and analyze the outcome. A treatment-regimen analysis counts everyone who was assigned to a drug, including people who stopped early. An efficacy analysis looks only at people who stayed on treatment and completed the protocol. The two approaches can produce different percentages from the same study, and online summaries often quote whichever number looks most impressive. Before you repeat any figure, go to the paper, find the analysis used, and check the study duration, the population included, and the rate of discontinuation due to adverse events.

It's also tempting to line up numbers from separate trials and declare a winner. Don't do that. STEP-1 and SURMOUNT-1 enrolled different populations, used different designs, and ran for different lengths of time. Only the head-to-head study answers the direct comparison question, and even then, the results describe a group, not a guarantee for any individual.

Dosing, titration, and the day-to-day routine

Neither medicine starts at its maintenance dose. Both follow a titration schedule that begins low and climbs in steps over several weeks. The idea is to give the body time to adjust, which tends to reduce gastrointestinal side effects. Starting doses, step increases, and maximum doses differ between semaglutide and tirzepatide. Read the prescribing information for the exact product you're considering, and confirm everything with your prescriber.

The weekly routine is simple in principle. You pick a consistent day, inject the pen as instructed, and keep track of when the next dose is due. Many people set a phone reminder or link the injection to something they already do each week. When the dose changes, the transition can feel different from one week to the next, so it helps to write down how you feel. Storage instructions vary between pens and products, and the rules printed in the prescribing information are the ones to follow.

Dose choice always depends on a prescription and on how well you tolerate the medicine. Switching from one drug to the other is not a do-it-yourself project. It requires a conversation with your doctor, because the dose equivalence, timing, and monitoring plan are individual decisions.

Side effects: what overlaps and what differs

Nausea, diarrhea, constipation, and abdominal discomfort show up with both medicines. How often they occur depends on the dose, the titration speed, and the study. Comparing frequencies across products is tricky, so use the adverse event tables in each prescribing information and in the trial papers rather than a single summary number. Our earlier post on stomach effects with semaglutide covers that topic in more depth, so there's no need to repeat it here.

Staying hydrated and adjusting meal size can make a real difference. Smaller, more frequent meals are a common approach, and some people find that very fatty or very sugary foods make symptoms worse. Keeping a daily log of what you ate and how you felt is a practical habit. Tracking symptoms gives your doctor concrete information instead of vague descriptions, and PeptPro readers who keep structured notes often find follow-up visits more productive.

Some warnings deserve urgent attention. Severe or persistent abdominal pain, especially pain that spreads to the back, and vomiting that won't stop are reasons to contact a doctor right away. The prescribing information for these medicines, which you can look up in the Bulário Eletrônico on ANVISA's website, also describes risks such as pancreatitis and gallbladder problems. That's why prompt medical evaluation matters if symptoms appear. The same documents list contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Make sure your doctor knows your family history before starting either one.

Access in Brazil: prescription, registration, and caveats

In Brazil, both semaglutide and tirzepatide require a prescription. Before you buy anything, check the product's registration status with ANVISA. A registered product has passed the agency's review, and that status is different from a similar product, a generic, or a compounded (manipulated) preparation. Each category follows its own rules, and ANVISA publishes the current resolutions on manipulated and generic medicines on its website, since the wording gets updated over time. Tirzepatide is sold in Brazil under the brand name Mounjaro. The approved indications may differ between products, for example between obesity and type 2 diabetes, so confirm which indication your prescription is for.

Be careful with prices that look too good to be true, with sellers whose origin you can't confirm, and with products that have no traceability, such as a missing batch number or no clear manufacturer. Prices change quickly, so don't rely on any number you find in an older article. For more detail on registration and safe purchasing of semaglutide in Brazil, our earlier posts on generic semaglutide go deeper, so this section only points you in that direction.

Questions to take to the doctor

Bringing a short list to your appointment makes the conversation more useful. Consider asking:

• What is my clinical goal, and how will you monitor my weight and blood tests to see whether the treatment is working?
• Do any of my conditions or current medications make one of these medicines a better fit than the other?
• What should I do if I develop intolerance, and when should I call the office instead of waiting for the next visit?

Weight loss with either medicine usually works best alongside changes in eating patterns, regular physical activity, and ongoing follow-up. Results vary a lot from person to person, and no medicine guarantees a specific outcome. These treatments can help some people lose weight, but they are not a cure. The decision about which one to use is individual and belongs to you and your doctor.

Keeping your own notes between visits can make those conversations sharper. Logging your weight each week, along with nausea, appetite changes, and bowel habits, gives you a clearer picture to bring to your care team. You can keep that record with PeptPro's tracking tools, and then review it together with your doctor, who will decide what the numbers mean for your plan. For official information on registered medicines, start with the ANVISA website at https://www.gov.br/anvisa/pt-br.

FAQ

Is tirzepatide more effective than semaglutide for weight loss?

The head-to-head SURMOUNT-5 trial compared the two directly, and tirzepatide produced greater average weight loss in that study. Individual results still vary, so the answer for you depends on your health profile and your doctor's assessment.

Can I switch from semaglutide to tirzepatide on my own?

No. Changing medicines requires a conversation with your prescriber, who will decide on the dose, the timing, and how to monitor you during the transition.

Do both medicines cause nausea?

Yes, nausea is among the most common side effects listed for both. Frequency depends on the dose and the titration speed, so check the prescribing information of the specific product you're considering.

Can I buy these medicines in Brazil without a prescription?

No. Both require a prescription, and you should confirm the product's registration status with ANVISA before buying. Avoid sellers who can't show traceability or a clear origin.

Sources

• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1), NEJM 2021
• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022
• Tirzepatide versus Semaglutide Once Weekly in Obesity (SURMOUNT-5), NEJM 2025
• ANVISA - Agência Nacional de Vigilância Sanitária
• ANVISA - Bulário Eletrônico (bulas de medicamentos registrados)